Bioventus (BVS) Capital Expenditures (2020 - 2026)

Bioventus (BVS) has 7 years of Capital Expenditures data on file, last reported at $534000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 281.43% year-over-year to $534000.0; the trailing twelve-month figure through Mar 2026 stood at $634000.0 (down 25.85% YoY), and the FY2025 full-year result was $240000.0, down 76.14% from the prior year.
• Capital Expenditures for Q1 2026 stood at $534000.0, up from $22000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $6.1 million in Q4 2023 and bottomed at -$5.2 million in Q4 2022.
• The 5-year median for Capital Expenditures is $534000.0 (2026), against an average of $624705.9.
• Peak annual rise in Capital Expenditures reached 1691.86% in 2025, while the deepest fall reached 1303.26% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$5.2 million in 2022, then surged by 217.38% to $6.1 million in 2023, then tumbled by 85.26% to $893000.0 in 2024, then sank by 97.54% to $22000.0 in 2025, then surged by 2327.27% to $534000.0 in 2026.
• The last three Capital Expenditures figures came in at $534000.0 (Q1 2026), $22000.0 (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.

Peer Comparison